Antibody Conjugate Therapeutics: Challenges and Potential

Antibody conjugates are a diverse class of therapeutics consisting of a cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells. The notion that antibodies directed toward targets on the surface of malignant cells could be used for drug delivery is not new.

  • Antibody-Drug Conjugates Design And Development
  • Bispecific antibody conjugates in therapeutics
  • Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
  • New Developments in Antibody-Drug Conjugates

Related Conference of Antibody Conjugate Therapeutics: Challenges and Potential

June 29-July 01, 2017

8th European Immunology Conference

Madrid, Spain
July 03-05, 2017

9th Asia-Pacific Global Summit on Healthcare & Immunology

Kuala Lumpur, Malaysia
July 12-13, 2017

3rd World Conference on Parasitology & Pathogenesis

Chicago, Illinois, USA
September 01-02, 2017

4th International Conference on Parasitology

Prague, Czech Republic
September 11-12, 2017

7th World Congress on Immunology

Amsterdam, Netherlands
November 2-3, 2017

9th World Congress and Expo on Immunology

Atlanta, Georgia, USA
November 02-03, 2017

9th World Congress on Immunity, Inflammation and Immunotherapies

Atlanta, Georgia, USA
November 06-07, 2017

2nd International Conference on Autoimmunity

Frankfurt, Germany
November 08-09, 2017

3rd Antibodies and Bio Therapeutics Congress & B2B

Las Vegas, Nevada, USA
November 13-14, 2017

5th International Conference on HIV/AIDS, STDs and STIs

Las Vegas, Nevada, USA
Dec 14-15, 2017

World Immunology Congress

Dubai, UAE
April 16-17, 2018

EuroSciCon Conference on StemCell

Amsterdam, Netherlands
July 05-07, 2018

EuroSciCon Conference on Immunology

Vienna, Austria

Antibody Conjugate Therapeutics: Challenges and Potential Conference Speakers

Recommended Sessions

Related Journals

Are you interested in